Current Mesalazine Products: Differences in Enteric-Coated Dosage Forms and Pharmaceutical Risks of Clinical Efficacy Reduction (Review)
INTRODUCTION. Oral mesalazine (5-aminosalicylic acid) products are commonly used to treat inflammatory bowel disease, in particular, ulcerative colitis. The clinical efficacy of these medicinal products depends directly on the composition and properties of the polymers used to deliver mes...
Saved in:
Main Authors: | S. Yu. Serebrova, V. V. Evteev, E. Yu. Demchenkova, M. V. Zhuravleva, A. B. Prokofiev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2024-12-01
|
Series: | Безопасность и риск фармакотерапии |
Subjects: | |
Online Access: | https://www.risksafety.ru/jour/article/view/456 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis
by: Yu. P. Uspenskiy, et al.
Published: (2022-03-01) -
4-aminosalicylic acid as a coupling reagent for spectrophotometric determination of mesalazine in an aqueous medium
by: Mohamed Y. Dhamra, et al.
Published: (2024-06-01) -
Mesalazine use tactics in the ulcerative colitis patients
by: A. V. Korolev, et al.
Published: (2013-03-01) -
Efficacy of mesalazine at ulcerative colitis with nutritional failure
by: A. V. Korolyov, et al.
Published: (2015-03-01) -
Features of rectal treatment of inflammatory bowel diseases
by: D. V. Egorov, et al.
Published: (2023-07-01)